The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese type 2 diabetic patients

Journal of Endocrinological Investigation

Volumn 32, Issue 1, 2009, Pages 69-73

  Duran, C ^a   Tuncel, E ^b   Ersoy, C ^b   Ercan, I ^b   Selimoglu, H ^b   Kiyici, S ^b   Guclu, M ^b   Erturk, E ^b   Imamoglu, S ^b  

^a Division of Endocrinology   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Acarbose; Insulin glargine; Repaglinide; Secondary failure; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; REPAGLINIDE;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE PAIN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

EID: 64549112201     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345682     Document Type: Article

References (30)

1. Genuth S. Insuline use in NIDDM. Diabetes Care 1990, 13: 1240-64.
2. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001, 24: 758-67.
3. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1992, 327: 1426-33.
4. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulphonylurea combination therapy in Type 2 diabetes, A metaanalysis of the randomised placebo-controlled trials. Arch Intern Med 1996, 156: 259-64.
5. Landstedt-Hallin L, Adamson U, Amer P, Bolinder J, Lins PE. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulphonylurea failure. Diabetes Care 1995, 18: 1183-6.
6. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR. Sulphonylurea inadequacy: Efficacy of addition of insulin over 6 years in patient with type 2 diabetes in the UK. Prospective Diabetes Study. (UKPDS 57). Diabetes Care 2002, 25: 330-6.
7. Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23: 1130-6.
8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26: 3080-6.
9. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes. 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24: 631-6.
10. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003, 20: 545-51.
11. Fritsche A, Schweitzer MA, Häring HU; 4001 study group. Glimepiride combined with mornig insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003, 138: 952-9.
12. Hirsch IB. Insulin analogues. N Engl J Med 2005, 352: 174-83.
13. Panelo A, Wing JR; AGEE-1272 Study Group, Repaglinide/bedtime NPH insulin is comparable to twice daily NPH insulin. Diabetes Care 2005, 28: 1789-90.
14. Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately conrolled with oral hypoglycaemic agents. Diabet Med 2003, 20: 935-41.
15. de Luis DA, Aller R, Cuellar L, et al. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001, 24: 1844-5.
16. de Luis DA, Aller R, Cuellar L, Terroba C, Romero E. Efficacy of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with diabetes mellitus. Diabetes 2002, 51 (Suppl 2): A468.
17. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993, 46: 1025-54.
18. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001, 52: 193-204.
19. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insuline dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994, 121: 928-35.
20. Coniff RF, Shapiro A Seaton TB, Bray GA. A multicenter, placebo controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide plus acarbose in non insuline dependent diabetes mellitus. Am J Med 1995, 98: 443-51.
21. Hwu CM, Ho LT, Fuh MM, et al; The Asian Acarbose Study Group. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: Result from a multinational, placebo controlled study. Diabetes Res Clin Pract 2003, 60: 111-8.
22. Standl E, Baumgartl HJ, Füchtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy in type 2 diabetic patient with late failure of sulphonylurea therapy. Diabetes Obes Metab 1999, 1: 215-20.
23. Rosak C, Hofmann U, Paulwitz O. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglind and combined acarbose/repaglinide application. Diabetes Nutr Metab 2004, 17: 137-42.
24. Holman RR, Turner RC. A Practial Guide to basal and prandial insulin therapy. Diabet Med 1985, 2: 45-53.
25. López-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, et al. Acarbose vs bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. Diabetes Obes Metab 1999, 11: 29-35.
26. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354; 617-21.
27. American Diabetes Association. Standarts of medical care in diabetes, Diabetes Care 2005, 28 (Suppl 1): S4-36.
28. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003, 111: 405-14.
29. Kelley DE, Bidot P, Freedman Z, et al. Efficacy and safety of acabose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998, 21: 2056-61.
30. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003, 25: 1541-77.